PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Authors:
- 2 March 2019
- journal article
- review article
- Published by Springer Nature in Frontiers of Medicine
- Vol. 13 (4) , 438-450
Abstract
Cervical cancer (CC) is the fourth most commonly diagnosed female malignancy and a leading cause of cancer-related mortality worldwide, especially in developing countries. Despite the use of advanced screening and preventive vaccines, more than half of all CC cases are diagnosed at advanced stages, when therapeutic options are extremely limited and side effects are severe. Given these circumstances, new and effective treatments are needed. In recent years, exciting progress has been made in immunotherapies, including the rapid development of immune checkpoint inhibitors. Checkpoint blockades targeting the PD-1/PD-L1 axis have achieved effective clinical responses with acceptable toxicity by suppressing tumor progression and improving survival in several tumor types. In this review, we summarize recent advances in our understanding of the PD-1/PD-L1 signaling pathway, including the expression patterns of PD-1/PD-L1 and potential PD-1/PD-L1-related therapeutic strategies for CC.Keywords
This publication has 97 references indexed in Scilit:
- PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck CancerCancer Research, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The PDL1-PD1 Axis Converts Human T H 1 Cells into Regulatory T CellsScience Translational Medicine, 2011
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1International Immunology, 2010
- The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface bindingProceedings of the National Academy of Sciences, 2009
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signalNature Immunology, 2009
- Persistence of High-Grade Cervical Dysplasia and Cervical Cancer Requires the Continuous Expression of the Human Papillomavirus Type 16 E7 OncogeneCancer Research, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Papillomaviruses and cancer: from basic studies to clinical applicationNature Reviews Cancer, 2002